{"url_path":"/sec/lipo/8-k/2026-07-15/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1347242/0001753926-26-001173-index.html","accession_number":"0001753926-26-001173","cik":"0001347242","ticker":"LIPO","issuer_name":"LIPELLA PHARMACEUTICALS INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1347242/0001753926-26-001173-index.html","primary_entity_key":"0001347242","primary_entity_name":"LIPELLA PHARMACEUTICALS INC."},"word_count":285,"has_tables":true,"body_markdown":"false\n0001347242\n\n0001347242\n\n2026-06-12\n2026-06-12\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n**UNITED\nSTATES\nSECURITIES AND EXCHANGE COMMISSION\nWashington, D.C. 20549**\n\n \n\n**FORM\n8-K**\n\n \n\n**CURRENT\nREPORT**\n\n**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**\n\n \n\n**Date\nof Report (Date of earliest event reported): June 12, 2026**\n\n \n\n**Lipella\nPharmaceuticals Inc.**\n\n**(Exact name of registrant as specified in its charter)**\n\n \n\nDelaware\n\n(State\nor other jurisdiction of incorporation)\n\n001-41575\n\n(Commission\nFile Number)\n\n20-2388040\n\n(I.R.S. Employer Identification No.)\n\n \n\n**1159\nS. Negley Avenue, Pittsburgh, PA 15217**\n\n**(Address of principal executive offices) (Zip Code)**\n\n \n\n**(412)\n894-1853**\n\n**(Registrant's telephone number, including area code)**\n\n \n\nCheck\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant\nunder any of the following provisions (*see* General Instruction A.2. below):\n\n \n\n \n☐\nWritten\ncommunications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)\n\n \n\n \n☐\nSoliciting\nmaterial pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)\n\n \n\n \n☐\nPre-commencement\ncommunication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))\n\n \n\n \n☐\nPre-commencement\ncommunication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))\n\n \n\nSecurities\nregistered pursuant to Section 12(b) of the Act: None.\n\n \n\nIndicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR\n§230.405 of this chapter) or Rule 20-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).\n\n \n\nEmerging\ngrowth company ☒\n\n \n\nIf\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for\ncomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\n \n\n 1"}